

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



COMMON SPLENDOR INTERNATIONAL HEALTH INDUSTRY GROUP LIMITED

(Incorporated in Bermuda with limited liability)

(Stock Code: 286)

CLARIFICATION ANNOUNCEMENT MAJOR AND CONTINUING CONNECTED TRANSACTION RENEWAL OF THE FACILITY AGREEMENT: THE NEW FACILITY AGREEMENT

Reference is made to the discloseable and continuing connected transaction announcement of Common Splendor International Health Industry Group Limited (the “**Company**”) dated 5 October 2018 (the “**Announcement**”) in relation to the renewal of the Facility Agreement under the New Facility Agreement dated 5 October 2018 entered into among the Company, Champion Dynasty and Mr. Cheung. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Board announces that, based on the reassessment of the Transaction by the Board, the Transaction constitutes a major and continuing connected transaction of the Company. The highest applicable percentage ratios in respect of the Transaction exceeds 100%. Given that the Transaction does not involve disposal or acquisition of assets, even the applicable ratios are more than 100%, the Transaction is regarded as a major transaction instead of a very substantial acquisition or very substantial disposal pursuant to Chapter 14 of the Listing Rules. Accordingly, the Transaction is subject to the reporting, announcement and shareholder’s approval requirements under Chapter 14 of the Listing Rules. In addition, the Transaction is subject to reporting, annual review, announcement and the Independent Shareholders approval requirements under Chapter 14A of the Listing Rules as disclosed in the Announcement, since one or more of the applicable percentage ratios of the Proposed Annual Caps for the Transaction exceed(s) 5%.

As disclosed in the Announcement, the Company will convene a SGM to seek approval from the Independent Shareholders in respect of the Transaction and the Proposed Annual Caps. A circular containing, among other things, (i) further information regarding the details of the Transaction; (ii) a letter of recommendation from the Independent Board Committee to the Independent Shareholders; (iii) a letter of advice from Gram Capital to the Independent Board Committee and the Independent Shareholders; and (iv) a notice of the SGM and other information as required under the Listing Rules will be despatched to the Shareholders on or before 29 October 2018.

By order of the Board of
**Common Splendor International
Health Industry Group Limited**
Wong Wing Cheung
Company Secretary

Hong Kong, 9 October 2018

As at the date of this announcement, the Board comprises Mr. Cheung Wai Kuen, Mr. Cheng Hau Yan and Mr. Ye Jiong Xian as executive Directors; Mr. Hou Kai Wen and Mr. Lin Jiang as non-executive Directors; and Mr. Lam Chi Wing, Mr. Mai Yang Guang and Mr. Wong Yiu Kit, Ernest as independent non-executive Directors.